- Home
- IMCR vs TFIN Comparison
IMCR vs TFIN Comparison
Compare IMCR & TFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- TFIN
- Stock Information
- Founded
- IMCR 2008
- TFIN 1981
- Country
- IMCR United Kingdom
- TFIN United States
- Employees
- IMCR N/A
- TFIN N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- TFIN Major Banks
- Sector
- IMCR Health Care
- TFIN Finance
- Exchange
- IMCR Nasdaq
- TFIN Nasdaq
- Market Cap
- IMCR 1.8B
- TFIN 1.5B
- IPO Year
- IMCR 2021
- TFIN N/A
- Fundamental
- Price
- IMCR $35.24
- TFIN $59.13
- Analyst Decision
- IMCR Buy
- TFIN Hold
- Analyst Count
- IMCR 8
- TFIN 4
- Target Price
- IMCR $57.00
- TFIN $70.75
- AVG Volume (30 Days)
- IMCR 281.5K
- TFIN 198.4K
- Earning Date
- IMCR 11-05-2025
- TFIN 10-15-2025
- Dividend Yield
- IMCR N/A
- TFIN N/A
- EPS Growth
- IMCR N/A
- TFIN N/A
- EPS
- IMCR N/A
- TFIN 0.44
- Revenue
- IMCR $356,145,000.00
- TFIN $409,227,000.00
- Revenue This Year
- IMCR $31.83
- TFIN $12.07
- Revenue Next Year
- IMCR $8.50
- TFIN $14.74
- P/E Ratio
- IMCR N/A
- TFIN $134.25
- Revenue Growth
- IMCR 26.78
- TFIN 2.49
- 52 Week Low
- IMCR $23.15
- TFIN $42.90
- 52 Week High
- IMCR $39.33
- TFIN $110.58
- Technical
- Relative Strength Index (RSI)
- IMCR 56.75
- TFIN 48.46
- Support Level
- IMCR $35.33
- TFIN $59.93
- Resistance Level
- IMCR $37.16
- TFIN $64.83
- Average True Range (ATR)
- IMCR 1.36
- TFIN 2.27
- MACD
- IMCR 0.32
- TFIN -0.26
- Stochastic Oscillator
- IMCR 53.39
- TFIN 35.05
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About TFIN Triumph Financial Inc.
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.